Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...

Central vision can fade slowly with age-related macular degeneration. Faces blur. Words smear on a page. A dark spot can sit ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

People with macular degeneration and other forms of central vision loss can see details like text and faces with this device.

Age-related macular degeneration, (AMD), is the leading cause of vision loss, affecting more than 10 million people in the United States alone. Traditional treatments require injections into the eye ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. The stock dropped 71% to 45 cents a share in after-hours ...